A peptidoform is one specific molecular form of the peptide — its sequence plus the modifications at given positions (HUPO-PSI term). This view preserves the reported terminal groups, residue modifications, and stereo markers from the source notation.

p-Glu-HWSYsLRP

Identity summarySpecific molecular form represented

Identity status: Specific molecular form represented
Residues: 9
Peptidoform features: 2
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0017481	—	—	—	Notation only	—

Residue view

Residue display

9 residues

N-termpGlu

E1H2W3S4Y5S6L7R8P9

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

Terminal modificationpos 1

pGlu

N-terminal pyroglutamate notation reported as p-Glu.

Reported residue markerpos 6

Lowercase residue token

A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.

Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

modified or textual

Parent-residue sequence

Residue string used for positional interpretation when available.

EHWSYSLRP

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached

3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors9 aa · pI 7.5 · GRAVY -1.42

Length: 9 aa
Monoisotopic mass: 1173.56 Da
Average mass: 1174.28 Da
Net charge at pH 7.4: 0.10
Estimated pI: 7.54
GRAVY: -1.422
KD-positive residues: 11.1%
Aromatic residues: 22.2%

Developability interpretation

Ionization context: pH 7.4 close to pI
Hydrophobicity balance: Leans hydrophilic
Amphipathic moment (μH): 1.28
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

2.97

pH 5

1.12

pH 6

0.77

pH 7.4

0.05

pH 9

-0.79

pH 12

-2.23

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)

1 · 11.1%

Basic (K,R,H)

2 · 22.2%

Polar uncharged (N,Q,S,T)

2 · 22.2%

Hydrophobic aliphatic (A,V,I,L,M)

1 · 11.1%

Aromatic (F,W,Y)

2 · 22.2%

Conformational / sulfur (G,P,C)

1 · 11.1%

Top residues

S222.2%R111.1%E111.1%H111.1%L111.1%P111.1%W111.1%Y111.1%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

3-9

WSYSLRP

GRAVY -0.871

Most hydrophilic window

2-8

HWSYSLR

GRAVY -1.100

3 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

Sequence is shorter than the local amphipathic-window sizes used here.

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Oxidation-sensitive residues

W · pos 3

Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 1.28100°/residue · 9 aa

Hydrophobic moment1.28

Mean K-D hydropathy-1.42

Approx. net charge0

Projection angle100° / residue

The pale sector marks the direction of the hydrophobic face inferred from μ_H. This is a projection assumption, not a measured fold.

HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμ_H arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μ_H arrow indicates an amphipathic helix, common in antimicrobial peptides.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Exposure / Absorption

11 records

What evidence describes systemic exposure or absorption?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeBioavailability Tmax AUC Cmax

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Bioavailability2 records · 1 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	100 %	Eligible when experimental context matches	UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum	Result: Reported point value · Molecular form: not reported · Route: subcutaneous · Source: Primary reference linked	Reference
2	70 %	Use only explicitly reported fields	Not specified	Result: Reported point value · Molecular form: not reported · Route: SC · 25 · Buserelin · exact product name match · exact or normalized match · Source: Primary reference linked	Source record

AUC4 records · 4 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	5.63 h*ng/mL	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow · plasma	Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked	Reference
2	5.99 h*ng/mL	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow · plasma	Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked	Reference
3	25.02 h*ng/mL	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig · plasma	Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked	Reference
4	25.75 h*ng/mL	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig · plasma	Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked	Reference

Cmax2 records · 2 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	2.68 ng/mL	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow · plasma	Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked	Reference
2	10.99 ng/mL	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig · plasma	Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked	Reference

Tmax3 records · 3 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	~ 1 hour ~ 3600 seconds	Eligible when experimental context matches	UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum	Result: Approximate quantitative measurement · Molecular form: not reported · Route: subcutaneous · Source: Primary reference linked	Reference
2	1.05 h 3780 seconds	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow · plasma	Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked	Reference
3	0.57 h 2052 seconds	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig · plasma	Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked	Reference

Distribution / Barrier

4 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopePlasma protein binding Vd

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd2 records · 2 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	839.88 L	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow · plasma	Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked	Reference
2	80.49 L	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig · plasma	Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked	Reference

Plasma protein binding2 records · 1 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	~ 15 %	Eligible when experimental context matches	UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum	Result: Approximate quantitative measurement · Molecular form: not reported · Source: Primary reference linked	Reference
2	15 %	Use only explicitly reported fields	plasma protein	Result: Reported point value · Molecular form: not reported · Route: NASAL, SC · 25 · Buserelin · exact product name match · exact or normalized match · Source: Primary reference linked	Source record

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

cell monolayer

BBB

barrier evidence

Excretion / Persistence

2 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeClearance

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Clearance2 records · 2 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	545.04 L/h	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow · plasma	Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked	Reference
2	41.15 L/h	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig · plasma	Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked	Reference

Evidence landscape

17 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

11 evidence records

Distribution / Barrier

4 evidence records

Metabolic & Proteolytic Stability

0 evidence records

Excretion / Persistence

2 evidence records

Toxicity / Safety

0 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Area Under Curve

Time To Max Concentration

Bioavailability

Clearance

Max Concentration

Plasma Protein Binding

Volume Of Distribution

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Clinical / product

Matrix / stability

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReferenceSpeciesMatrixRoute

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Exposure / Absorption Exposure	Bioavailability	100 %	Reported point value	Eligible when experimental context matches	UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum	Route: subcutaneous · Suprecur Injection 1 mg/mL solution for injection.	Reference Primary reference linked
2	Exposure / Absorption Exposure	Time To Max Concentration	~ 1 hour ~ 3,600 seconds	Approximate quantitative measurement	Eligible when experimental context matches	UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum	Route: subcutaneous · Suprecur Injection 1 mg/mL solution for injection.	Reference Primary reference linked
3	Distribution / Barrier Distribution	Plasma Protein Binding	~ 15 %	Approximate quantitative measurement	Eligible when experimental context matches	UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum	Suprecur Injection 1 mg/mL solution for injection.	Reference Primary reference linked
4	Distribution / Barrier Distribution	Plasma Protein Binding	15 %	Reported point value	Use only explicitly reported fields	plasma protein	Route: NASAL, SC	Source record Primary reference linked
5	Exposure / Absorption Exposure	Bioavailability	70 %	Reported point value	Use only explicitly reported fields	Not specified	Route: SC	Source record Primary reference linked
6	Exposure / Absorption Exposure	Area Under Curve	25.02 h*ng/mL	Reported point value	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig...	Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Animal plasma PK after single intramuscular buserelin administration. Apparent parameters preserve the source se...	Reference Primary reference linked
7	Exposure / Absorption Exposure	Area Under Curve	5.63 h*ng/mL	Reported point value	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow...	Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Animal plasma PK after single intramuscular buserelin administration. Apparent parameters preserve the source se...	Reference Primary reference linked
8	Exposure / Absorption Exposure	Area Under Curve	25.75 h*ng/mL	Reported point value	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig...	Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Animal plasma PK after single intramuscular buserelin administration. Apparent parameters preserve the source se...	Reference Primary reference linked
9	Exposure / Absorption Exposure	Area Under Curve	5.99 h*ng/mL	Reported point value	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow...	Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Animal plasma PK after single intramuscular buserelin administration. Apparent parameters preserve the source se...	Reference Primary reference linked
10	Exposure / Absorption Exposure	Max Concentration	10.99 ng/mL	Reported point value	Eligible when experimental context matches	UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig...	Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Animal plasma PK after single intramuscular buserelin administration. Apparent parameters preserve the source se...	Reference Primary reference linked

1–10 / 17

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

Summary1 linked product

Linked products: 1
Label context: None
Clinical trials: 26
Safety label cues: None

Linked products1 shown

Buserelin

Peptide-product match

Unique peptide match

Route / product class

Nasal spray

Clinical context

26 trial records · 8 exact intervention matches · 7 with results · latest 2026-04-08

Label safety context

No label safety cue linked

View product

Identity & reference map

17 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary3 reference groups

Identity type: reported modified sequence
Reported notation: 1
Reference groups: 3
Measurements: 17
ATL peptide ID: ATLPC0015943

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 17

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 17

Different notation

Reported notation does not resolve to the current display sequence.

2 / 17

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

15 / 17

Reported sequence notation

Different2 references

XHWSYXLRP-NHEt

Current identity

p-Glu-HWSYsLRP

Reported names

No distinct human-readable aliases are exposed.

Reference map3 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	DistributionExposurePersistence Area Under Curve, Clearance, Max Concentration, Time To Max Concentration +1 more	No reported alias	12 identity 12 evidence
Reference Open	DistributionExposure Bioavailability, Plasma Protein Binding, Time To Max Concentration	No reported alias	3 identity 3 evidence
Source record Open	DistributionExposure Bioavailability, Plasma Protein Binding	No reported alias XHWSYXLRP-NHEtdifferent	2 identity 2 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0015943
Identity type: reported modified sequence
ADMET endpoints: 7
Evidence records: 17
Reference groups: 3
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0015943

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0015943' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0017481

—

Notation only

—

Value

Analysis use

Assay / model

Result context

Reference

100 %

Eligible when experimental context matches

UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum

Result: Reported point value · Molecular form: not reported · Route: subcutaneous · Source: Primary reference linked

Reference

70 %

Use only explicitly reported fields

Not specified

Result: Reported point value · Molecular form: not reported · Route: SC · 25 · Buserelin · exact product name match · exact or normalized match · Source: Primary reference linked

Source record

Value

Analysis use

Assay / model

Result context

Reference

5.63 h*ng/mL

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow · plasma

Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked

Reference

5.99 h*ng/mL

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow · plasma

Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked

Reference

25.02 h*ng/mL

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig · plasma

Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked

Reference

25.75 h*ng/mL

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig · plasma

Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

2.68 ng/mL

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow · plasma

Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked

Reference

10.99 ng/mL

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig · plasma

Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

~ 1 hour

~ 3600 seconds

Eligible when experimental context matches

UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum

Result: Approximate quantitative measurement · Molecular form: not reported · Route: subcutaneous · Source: Primary reference linked

Reference

1.05 h

3780 seconds

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow · plasma

Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked

Reference

0.57 h

2052 seconds

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig · plasma

Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

839.88 L

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow · plasma

Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked

Reference

80.49 L

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig · plasma

Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

~ 15 %

Eligible when experimental context matches

UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum

Result: Approximate quantitative measurement · Molecular form: not reported · Source: Primary reference linked

Reference

15 %

Use only explicitly reported fields

plasma protein

Result: Reported point value · Molecular form: not reported · Route: NASAL, SC · 25 · Buserelin · exact product name match · exact or normalized match · Source: Primary reference linked

Source record

Value

Analysis use

Assay / model

Result context

Reference

545.04 L/h

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow · plasma

Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked

Reference

41.15 L/h

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig · plasma

Result: Reported point value · Molecular form: not reported · Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Source: Primary reference linked

Reference

ADMET domain

Endpoint

Reported value

Result type

Analysis use

Assay / model

Condition

Reference

Exposure / Absorption

Exposure

Bioavailability

100 %

Reported point value

Eligible when experimental context matches

UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum

Route: subcutaneous · Suprecur Injection 1 mg/mL solution for injection.

Reference

Primary reference linked

Exposure / Absorption

Exposure

Time To Max Concentration

~ 1 hour

~ 3,600 seconds

Approximate quantitative measurement

Eligible when experimental context matches

UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum

Route: subcutaneous · Suprecur Injection 1 mg/mL solution for injection.

Reference

Primary reference linked

Distribution / Barrier

Distribution

Plasma Protein Binding

~ 15 %

Approximate quantitative measurement

Eligible when experimental context matches

UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum

Suprecur Injection 1 mg/mL solution for injection.

Reference

Primary reference linked

Distribution / Barrier

Distribution

Plasma Protein Binding

15 %

Reported point value

Use only explicitly reported fields

plasma protein

Route: NASAL, SC

Source record

Primary reference linked

Exposure / Absorption

Exposure

Bioavailability

70 %

Reported point value

Use only explicitly reported fields

Not specified

Route: SC

Source record

Primary reference linked

Exposure / Absorption

Exposure

Area Under Curve

25.02 h*ng/mL

Reported point value

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig...

Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Animal plasma PK after single intramuscular buserelin administration. Apparent parameters preserve the source se...

Reference

Primary reference linked

Exposure / Absorption

Exposure

Area Under Curve

5.63 h*ng/mL

Reported point value

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow...

Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Animal plasma PK after single intramuscular buserelin administration. Apparent parameters preserve the source se...

Reference

Primary reference linked

Exposure / Absorption

Exposure

Area Under Curve

25.75 h*ng/mL

Reported point value

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig...

Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Animal plasma PK after single intramuscular buserelin administration. Apparent parameters preserve the source se...

Reference

Primary reference linked

Exposure / Absorption

Exposure

Area Under Curve

5.99 h*ng/mL

Reported point value

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · cow...

Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Animal plasma PK after single intramuscular buserelin administration. Apparent parameters preserve the source se...

Reference

Primary reference linked

Exposure / Absorption

Exposure

Max Concentration

10.99 ng/mL

Reported point value

Eligible when experimental context matches

UPLC-MS/MS plasma PK study with WinNonlin noncompartmental analysis; manual extraction from peer-reviewed Table 8 · pig...

Route: intramuscular · Dose/window: 0-8 h post-dose serial plasma sampling · Animal plasma PK after single intramuscular buserelin administration. Apparent parameters preserve the source se...

Reference

Primary reference linked

Reference

Supports

Reported identity

Records

Reference

Open

DistributionExposurePersistence

Area Under Curve, Clearance, Max Concentration, Time To Max Concentration +1 more

No reported alias

12 identity

12 evidence

Reference

Open

DistributionExposure

Bioavailability, Plasma Protein Binding, Time To Max Concentration

No reported alias

3 identity

3 evidence

Source record

Open

DistributionExposure

Bioavailability, Plasma Protein Binding

No reported alias

XHWSYXLRP-NHEtdifferent

2 identity

2 evidence